Right. And this is in sharp contrast to MNTA executives who are adamant their copax is the same. Good info. Thanks for the response and I echo your sentiments.
<<Bottom line: As a MNTA shareholder, I now feel slightly more confident that MNTA will get Copaxone approval before MYL.>>
That's it? Slightly more confident??
What happened to the bravado? I.e, Teva has no chance of approval (merely a knockoff) and Amphastar has even LESS of a shot (their submission is a total joke and in tatters)??
This brush with reality could actually wind up being the most bullish signal MNTA has gotten in years, if ever
Market Data 
Markets 
AI
